Amneal Pharmaceuticals, Inc. - Class A (AMRX) earnings
AMRX earnings moved a median of 0.00% by the close. Quarterly and annual AMRX reports and results, each read against the price at its own news timestamp. Back to the AMRX overview →
33 measured AMRX earnings events.
Where these AMRX earnings landedvs 33 measured AMRX earnings reactions
| Middle 50% of AMRX earnings reactions | -1.93% to +2.61% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 33 |
Point-in-time · zero look-ahead
Half of the 33 AMRX earnings events with a measured close landed between -1.93% and +2.61%; 42% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Amneal to Report Third Quarter 2026 Results on November 3, 2026 | Press release | -1.09% | +0.00% | |
| Form 10-Q Amneal Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -1.05% | -0.06% | |
| Amneal Reports Second Quarter 2026 Financial Results | Press release | -0.06% | +1.54% | |
| Amneal to Report Second Quarter 2026 Results on July 30, 2026 | Press release | -0.65% | +0.59% | |
| Amneal Reports First Quarter 2026 Financial Results | Press release | -0.73% | -4.21% | |
| Form 10-Q Amneal Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | -0.73% | -4.21% | |
| Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance | Press release | +2.64% | -3.39% | |
| Amneal to Report First Quarter 2026 Results on May 1, 2026 | Press release | -0.79% | -0.16% | |
| Form 10-K Amneal Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | -0.67% | -0.72% | |
| Form 10-Q Amneal Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -0.77% | -2.49% | |
| Amneal Reports Third Quarter 2025 Financial Results | Press release | -5.03% | -5.93% | |
| Amneal to Report Third Quarter 2025 Results on October 30, 2025 | Press release | +1.20% | +3.70% | |
| Form 10-Q Amneal Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | +0.49% | +4.02% | |
| Amneal Reports Second Quarter 2025 Financial Results | Press release | -1.21% | -1.93% | |
| Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results | Press release | -0.56% | -1.25% | |
| Amneal to Report Second Quarter 2025 Results on August 5, 2025 | Press release | +0.65% | -1.30% | |
| Form 10-Q Amneal Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +0.69% | +3.32% | |
| Amneal Reports First Quarter 2025 Financial Results | Press release | -5.26% | +2.31% | |
| Amneal to Report First Quarter 2025 Results on May 2, 2025 | Press release | +0.51% | +8.79% | |
| Form 10-K Amneal Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +1.09% | +0.81% | |
| Form 10-Q Amneal Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -0.97% | -2.59% | |
| Amneal Reports Third Quarter 2024 Financial Results | Press release | -2.64% | +7.12% | |
| Amneal to Report Third Quarter 2024 Results on November 8, 2024 | Press release | -0.23% | +0.23% | |
| Amneal Reports Second Quarter 2024 Financial Results | Press release | +1.71% | -0.26% | |
| Form 10-Q Amneal Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -4.25% | -2.96% | |
| Amneal to Report Second Quarter 2024 Results on August 9, 2024 | Press release | -0.96% | -1.78% | |
| Form 10-Q Amneal Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +0.30% | -2.85% | |
| Amneal Reports First Quarter 2024 Financial Results | Press release | -4.32% | +8.16% | |
| Amneal to Report First Quarter 2024 Results on May 3, 2024 | Press release | +0.61% | +0.00% | |
| Form 10-K Amneal Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +1.31% | +2.61% | |
| Form 10-Q Amneal Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -1.93% | +0.00% | |
| Amneal Reports Third Quarter 2023 Financial Results | Press release | +2.39% | +3.11% | |
| Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance | Press release | +9.04% | +12.99% |
Keep exploring
More AMRX: analyst actions → · SEC filings → · AMRX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| REPRO MED SYSTEMS INC (REPR) | 378 | 0.00% | 26% |
| Akebia Therapeutics, Inc. (AKBA) | 377 | 0.00% | 49% |
| Autolus Therapeutics plc - American Depositary Shares (AUTL) | 377 | -0.00% | 45% |
| Solid Biosciences Inc. (SLDB) | 375 | -0.17% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.